New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
18:07 EDTCLDNCelladon 4M share Secondary priced at $9.50
Credit Suisse and Jefferies acted as joint book running managers for the offering.
News For CLDN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
16:43 EDTCLDNEnterprise Partners reports 8.3% passive stake in Celladon
Subscribe for More Information
March 26, 2015
13:34 EDTCLDNCelladon volatility elevated into Q4 and trial outcome
Celladon April call option implied volatility is at 173, May is at 322, June is at 277; compared to its 7-week average of 220 according to Track Data, suggesting large May price movement into the expected release of Q4 results on March 31 and outcome of the CUPID2 trial.
March 25, 2015
10:51 EDTCLDNOptions with increasing implied volatility
Options with increasing implied volatility: CLDN CMG CREE AMZN ISRG MAC UA VMW SLXP
March 24, 2015
19:40 EDTCLDNOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTCLDNCelladon, Novasep execute Mydicar API supply agreement
Celladon and Novasep announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming Mydicar clinical data, Novasep would manufacture Mydicar drug substance through 2018 with extension options through 2020. The contract follows an earlier letter agreement concerning the initial process transfer of Mydicar and pre-validation studies, which was signed in December 2014. The new agreement continues the work necessary for Novasep to achieve GMP production of Mydicar drug substance. Under the terms of the agreement, Novasep and Celladon would conduct the process transfer, development, facility retrofitting and scale-up activities necessary to carry out production of Mydicar drug substance in a 2000L bioreactor at an enhanced bioproduction plant in Seneffe, Belgium. GMP operations are planned to start in 4Q16 and continue through 2018. An option to extend through 2020 will be determined based on Celladon's requirements for the Mydicar drug substance. Celladon has the right to terminate the agreement, exercisable for a specified period of time following the un-blinding of the data from the CUPID2 study, if Celladon concludes in good faith that the CUPID2 data is such that Celladon does not require production of Mydicar drug substance at the Novasep facility.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use